Jefferies Keeps Their Hold Rating on West Pharmaceutical Services (WST)

Jefferies analyst David Windley maintained a Hold rating on West Pharmaceutical Services (WSTResearch Report) on July 11 and set a price target of $333.00. The company’s shares closed last Thursday at $294.15, close to its 52-week low of $275.89.

According to, Windley is a top 100 analyst with an average return of 15.3% and a 68.9% success rate. Windley covers the Healthcare sector, focusing on stocks such as Molina Healthcare, Elevance Health, and Stevanato Group.

West Pharmaceutical Services has an analyst consensus of Moderate Buy, with a price target consensus of $381.00.

See today’s best-performing stocks on TipRanks >>

West Pharmaceutical Services’ market cap is currently $22.22B and has a P/E ratio of 33.32.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

West Pharmaceutical Services, Inc. manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. It operates through the following business segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services, to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. The company was founded by Herman O. West on July 27, 1923 and is headquartered in Exton, PA.

Read More on WST:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More